MICA and plasma cell myeloma: Another recent study has reported that BETi can increase NK cell-activating ligand MICA expression via Brd4 inhibition-modulated downregulation of IRF4, a transcriptional repressor of MICA, leading to enhanced NK cell-mediated cytotoxicity against multiple myeloma cells [156].